Common Contracts
5 similar Sales Agreement contracts by Axovant Gene Therapies Ltd., uniQure N.V., Sio Gene Therapies Inc.
uniQure N.V. Up to $200,000,000 of Ordinary Shares (nominal value €0.05 per share) SALES AGREEMENTSales Agreement • March 2nd, 2021 • uniQure N.V. • Pharmaceutical preparations • New York
uniQure N.V., a Dutch public company with limited liability (naamloze vennootschap) (the “Company”), confirms its agreement (this “Agreement”) with SVB Leerink LLC (“ SVB Leerink”), as follows:
SIO GENE THERAPIES INC. COMMON STOCK SALES AGREEMENTSales Agreement • December 18th, 2020 • Sio Gene Therapies Inc. • Pharmaceutical preparations • New York
AXOVANT GENE THERAPIES LTD. COMMON SHARES SALES AGREEMENTSales Agreement • June 11th, 2020 • Axovant Gene Therapies Ltd. • Pharmaceutical preparations • New York
Axovant Gene Therapies Ltd. (the “Company”), confirms its agreement (this “Agreement”) with SVB Leerink LLC (“SVB Leerink”), as follows:
AXOVANT GENE THERAPIES LTD. COMMON SHARES SALES AGREEMENTSales Agreement • April 29th, 2020 • Axovant Gene Therapies Ltd. • Pharmaceutical preparations • New York
Axovant Gene Therapies Ltd. (the “Company”), confirms its agreement (this “Agreement”) with SVB Leerink LLC (“SVB Leerink”), as follows:
uniQure N.V. Up to 5,000,000 Ordinary Shares (nominal value €0.05 per share) SALES AGREEMENTSales Agreement • September 18th, 2017 • uniQure N.V. • Pharmaceutical preparations • New York
uniQure N.V., a Dutch public company with limited liability (naamloze vennootschap) (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (“Leerink”), as follows:
